Decoy Therapeutics (NASDAQ:DCOY – Get Free Report) and ProMetic Life Sciences (OTCMKTS:PFSCF – Get Free Report) are both small-cap manufacturing companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.
Profitability
This table compares Decoy Therapeutics and ProMetic Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Decoy Therapeutics | N/A | -401.05% | -155.77% |
| ProMetic Life Sciences | -894.02% | -3,350.55% | -67.76% |
Analyst Ratings
This is a breakdown of current recommendations for Decoy Therapeutics and ProMetic Life Sciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Decoy Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
| ProMetic Life Sciences | 0 | 0 | 0 | 0 | 0.00 |
Insider and Institutional Ownership
11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of ProMetic Life Sciences shares are owned by institutional investors. 0.3% of Decoy Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk & Volatility
Decoy Therapeutics has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, ProMetic Life Sciences has a beta of 2.46, suggesting that its share price is 146% more volatile than the S&P 500.
Earnings and Valuation
This table compares Decoy Therapeutics and ProMetic Life Sciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Decoy Therapeutics | N/A | N/A | -$5.58 million | ($33.89) | -0.23 |
| ProMetic Life Sciences | $36.55 million | 3.49 | -$150.73 million | N/A | N/A |
Decoy Therapeutics has higher earnings, but lower revenue than ProMetic Life Sciences.
Summary
Decoy Therapeutics beats ProMetic Life Sciences on 8 of the 11 factors compared between the two stocks.
About Decoy Therapeutics
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
About ProMetic Life Sciences
Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.
Receive News & Ratings for Decoy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Decoy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
